ClinicalTrials.gg
RecruitingNCT07611110VECTRA-01Updated Oct 19, 2026

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

A Phase 3 interventional study of Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) and Cabazitaxel in Metastatic Castration-resistant Prostate Cancer, sponsored by AstraZeneca. Recruiting at 151 sites in 24 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 19, 2026First sites in 4 new countriesSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
670
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Planned enrollment
15th of 60
670 · median 110
Started
2026
with 6 others
Phase 3
17 of 91
3 open now
Primary completion
2029-06
later than 22 of 28 live
Registered
87th of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 15th largest by planned enrollment of the 60 interventional ones that give a count, is one of 7 that started in 2026, is one of 17 in phase 3, reaches primary completion later than 22 of the 28 other live ones, and was the 87th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.

Read the detailed description

Approximately 670 adult participants with mCRPC will be randomized to receive either AZD2265 or standard of care treatment (investigator's choice of cabazitaxel, ARPI, or radium-223). They will receive their assigned treatment until disease progression, unacceptable toxicity, or other discontinuation criteria are met. Tumor evaluation scans will continue after treatment discontinuation until radiographically confirmed progression or death.

All patients will be followed for survival until the end of the study. An Independent Data Monitoring Committee (IDMC) composed of independent experts will be convened to monitor the safety and scientific integrity of the study.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • AZD2265; prostate cancer; mCRPC; PSMA; FPI-2265; 225Ac; Actinium (225Ac) zadavotide guraxetan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age.
  • Diagnosis of adenocarcinoma of prostate.
  • Must have had prior orchiectomy and/or ongoing ADT and a castrate level of plasma/serum testosterone.
  • Progressive mCRPC following the most recent treatment at the time of study entry, with at least 1 lesion (measurable and/or non-measurable) that is suitable for repeated assessment by CT and/or MRI and/or bone scan.
  • Previously treated with at least 2 cycles of PSMA-directed β-emitting radioconjugate.
  • Previously treated with at least 1 taxane-based chemotherapy regimen for either metastatic hormone-sensitive prostate cancer or CRPC.
  • Previously treated with at least 1 ARPI (eg, enzalutamide, abiraterone, etc.).
  • Positive PSMA PET/CT scans, obtained with PSMA ligands (⁶⁸Ga-PSMA-11 or ¹⁸F-DCFPyL).
  • performance status of 0 to 2.
  • Adequate organ and bone marrow function as described in study protocol.
  • Participants must not father children or donate sperm from signing ICF, during the study intervention and for 6 months after the last dose of study intervention.
  • Participants must use a condom from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with an α-emitting molecular targeted therapeutic radioconjugate (prior treatment with radium-223 is permitted).
  • Progression on PSMA-directed β-emitting radioconjugate prior to the administration of Cycle 3.
  • Receipt of > 6 cycles of PSMA-directed β-emitting therapeutic RC.
  • History of another primary , with exceptions.
  • Persistent toxicities ( Grade ≥ 2) caused by previous anticancer therapy, with exceptions.
  • Spinal cord compression or unless asymptomatic, stable, and not requiring for at least 4 weeks prior to start of study intervention.
  • abnormalities, with exceptions.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
670 participants (estimated)

Study arms

  • Experimental
    Arm A

    Actinium (225Ac) zadavotide guraxetan (AZD2265 \[FPI-2265\])

    Drug: Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])

  • Active comparator
    Arm B

    Investigator's choice of cabazitaxel, ARPI, or radium-223

    Drug: Cabazitaxel · Drug: Abiraterone · Drug: Enzalutamide · Drug: Apalutamide · Drug: Darolutamide · Drug: Deutenzalutamide · Drug: Radium-223

Interventions

  • IV

    Also known as: AZD2265, FPI-2265

  • IV in combination with oral prednisone/prednisolone

    Also known as: Jevtana

  • Oral in combination with prednisone/prednisolone

    Also known as: Zytiga

  • Oral

    Also known as: Xtandi

  • Oral; Available only to participants randomized under Protocol Version 2.0; not offered to participants randomized under Protocol Version 3.0 (04 June 2026)

    Also known as: Erleada

  • Oral; Available only to participants randomized under Protocol Version 2.0; not offered to participants randomized under Protocol Version 3.0 (04 June 2026)

    Also known as: Nubeqa

  • Oral; available in China only

  • IV

    Also known as: Xofigo

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-Free Survival (rPFS)

    rPFS is defined as the time from randomisation to radiographic progression, as assessed by the BICR per RECIST 1.1 (soft tissue) and/or PCWG3 criteria (bone), or death due to any cause.

    Time frame: From randomization until first radiographic progression per RECIST 1.1/PCWG3 by BICR, or death from any cause, whichever occurs first (up to approximately 33 months)

  2. Overall Survival (OS)

    OS is defined as the length of time from randomisation until the date of death due to any cause.

    Time frame: From randomization until death from any cause (up to approximately 33 months)

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from randomisation to the earliest of progression (defined as radiographic progression assessed by BICR per RECIST 1.1 and/or PCWG3 criteria, clinical progression, or PSA progression), or death due to any cause.

    Time frame: From randomization until first documented progression (radiographic, clinical, or PSA progression) or death in the absence of progression, whichever occurs first (up to approximately 33 months)

  2. Assessment of PSA50 (≥50% prostate-specific antigen reduction)

    Proportion of participants achieving a \>= 50% decrease in PSA from baseline.

    Time frame: From C1D1, assessed each treatment cycle then every 8 weeks after EOT until BICR-assessed radiographic progression per RECIST 1.1/PCWG3 (up to approximately 33 months)

  3. Assessment of PSA90 (≥90% prostate-specific antigen reduction)

    Proportion of participants achieving \>=90% decrease in PSA from baseline.

    Time frame: From C1D1, assessed each treatment cycle then every 8 weeks after EOT until BICR-assessed radiographic progression per RECIST 1.1/PCWG3 (up to approximately 33 months)

  4. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants with measurable soft tissue disease at baseline who have a CR or PR as determined by BICR, per RECIST 1.1 (soft tissue) and PCWG3 criteria (bone).

    Time frame: From baseline; assessed by BICR per RECIST 1.1/PCWG3 every 8 weeks for first 32 weeks, then every 12 weeks until radiographic progression (up to approximately 33 months)

  5. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1 (soft tissue) and/or PCWG3 criteria (bone) as determined by BICR or death in the absence of disease progression.

    Time frame: From first documented response until progression per RECIST 1.1/PCWG3 by BICR, or death in the absence of progression, whichever occurs first (up to approximately 33 months)

  6. Symptomatic Skeletal Event-Free Survival (SSE-FS)

    SSE-FS is defined as the time from randomisation to the earliest of the following: * Use of radiation therapy to prevent or relieve skeletal symptoms. * Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral). * Occurrence of spinal cord compression. * Orthopaedic surgical intervention for bone metastasis. * Death due to any cause.

    Time frame: From randomization until first symptomatic skeletal event or death from any cause, whichever occurs first (up to approximately 33 months)

  7. Plasma concentrations of AZD2265

    Plasma concentrations of AZD2265 pre-dose and post-dose.

    Time frame: Pre-dose and post-dose on Day 1 of Cycles 1 and 2; 3-24 hours post-dose on Cycle 1 Day 1 only (up to approximately 7 weeks)

07

Study locations

19 of 151 sites recruiting
  • Research Site
    Dothan, Alabama 36303, United States
    Recruiting
  • Research Site
    Phoenix, Arizona 85004, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Duarte, California 91010, United States
    Recruiting
  • Research Site
    Irvine, California 92618, United States
    Not yet recruiting
  • Research Site
    Newport Beach, California 92660, United States
    Recruiting
  • Research Site
    San Francisco, California 94143, United States
    Recruiting
  • Research Site
    Aurora, Colorado 80045, United States
    Not yet recruiting
  • Research Site
    Miami, Florida 33165, United States
    Recruiting
  • Research Site
    O'Fallon, Illinois 62269, United States
    Not yet recruiting
  • Research Site
    Metairie, Louisiana 70006, United States
    Recruiting
  • Research Site
    Westbrook, Maine 04092, United States
    Not yet recruiting
  • Research Site
    Detroit, Michigan 48201, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Grand Rapids, Michigan 49503, United States
    Not yet recruiting
  • Research Site
    St Louis, Missouri 63104, United States
    Not yet recruiting
  • Research Site
    Omaha, Nebraska 68130, United States
    Recruiting
  • Research Site
    Albuquerque, New Mexico 87109, United States
    Not yet recruiting
  • Research Site
    New Hyde Park, New York 11042, United States
    Not yet recruiting
  • Research Site
    New York, New York 10065, United States
    Recruiting
  • Research Site
    Cleveland, Ohio 44115, United States
    Not yet recruiting
  • Research Site
    Cleveland, Ohio 44195, United States
    Not yet recruiting
  • Research Site
    Dayton, Ohio 45415, United States
    Not yet recruiting
  • Research Site
    Portland, Oregon 97239, United States
    Not yet recruiting
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
    Recruiting
  • Research Site
    Nashville, Tennessee 37203, United States
    Recruiting
  • Research Site
    Houston, Texas 77042, United States
    Recruiting
  • Research Site
    Salt Lake City, Utah 84106, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Tacoma, Washington 98405, United States
    Not yet recruiting
  • Research Site
    Darlinghurst, 2010, Australia
    Not yet recruiting
  • Research Site
    Kurralta Park, 5037, Australia
    Not yet recruiting
  • Research Site
    Melbourne, 3000, Australia
    Recruiting
  • Research Site
    Murdoch, WA6150, Australia
    Not yet recruiting
  • Research Site
    Linz, 4020, Austria
    Not yet recruiting
  • Research Site
    Salzburg, 5020, Austria
    Not yet recruiting
  • Research Site
    Vienna, 1090, Austria
    Not yet recruiting
  • Research Site
    Ghent, 9000, Belgium
    Not yet recruiting
  • Research Site
    Leuven, 3000, Belgium
    Not yet recruiting
  • Research Site
    Liège, 4000, Belgium
    Not yet recruiting
  • Research Site
    São Paulo, 01308-050, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 05652-900, Brazil
    Not yet recruiting
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
    Not yet recruiting
  • Research Site
    Halifax, Nova Scotia B3H 1V7, Canada
    Not yet recruiting
  • Research Site
    Hamilton, Ontario L8V 1C3, Canada
    Not yet recruiting
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
    Not yet recruiting
  • Research Site
    Montreal, Quebec H3A 1A1, Canada
    Recruiting
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
  • Research Site
    Beijing, 100034, China
    Not yet recruiting
  • Research Site
    Beijing, 100142, China
    Not yet recruiting
  • Research Site
    Chengdu, 610041, China
    Not yet recruiting
  • Research Site
    Chongqing, 400030, China
    Not yet recruiting
  • Research Site
    Fuzhou, 350005, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510060, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510120, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510630, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310003, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310014, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310022, China
    Not yet recruiting
  • Research Site
    Jinan, 250117, China
    Not yet recruiting
  • Research Site
    Nanjing, 210006, China
    Not yet recruiting
  • Research Site
    Nanjing, 210029, China
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Shanghai, 200025, China
    Not yet recruiting
  • Research Site
    Shanghai, 200032, China
    Not yet recruiting
  • Research Site
    Shenyang, 110001, China
    Not yet recruiting
  • Research Site
    Suzhou, 215006, China
    Not yet recruiting
  • Research Site
    Wuhan, 430022, China
    Not yet recruiting
  • Research Site
    Wuhan, 430030, China
    Not yet recruiting
  • Research Site
    Xi'an, 710061, China
    Not yet recruiting
  • Research Site
    Kuopio, 70210, Finland
    Not yet recruiting
  • Research Site
    Villejuif, 94800, France
    Not yet recruiting
  • Research Site
    Augsburg, 86156, Germany
    Not yet recruiting
  • Research Site
    Berlin, 13353, Germany
    Not yet recruiting
  • Research Site
    Bonn, 53127, Germany
    Not yet recruiting
  • Research Site
    Cologne, 50937, Germany
    Not yet recruiting
  • Research Site
    Dresden, 01307, Germany
    Not yet recruiting
  • Research Site
    Essen, 45122, Germany
    Not yet recruiting
  • Research Site
    Jena, 07747, Germany
    Not yet recruiting
  • Research Site
    Karlsruhe, 76133, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    München, 81675, Germany
    Not yet recruiting
  • Research Site
    Münster, 48149, Germany
    Not yet recruiting
  • Research Site
    Nuremberg, 90419, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Rostock, 18057, Germany
    Not yet recruiting
  • Research Site
    Stuttgart, 70174, Germany
    Not yet recruiting
  • Research Site
    Tübingen, 72076, Germany
    Not yet recruiting
  • Research Site
    Würzburg, 97080, Germany
    Not yet recruiting
  • Research Site
    Bangalore, 560017, India
    Not yet recruiting
  • Research Site
    Gūrgaon, 122001, India
    Not yet recruiting
  • Research Site
    Gūrgaon, 122002, India
    Not yet recruiting
  • Research Site
    Navi Mumbai, 410210, India
    Not yet recruiting
  • Research Site
    Haifa, 3109601, Israel
    Not yet recruiting
  • Research Site
    Jerusalem, 00000, Israel
    Not yet recruiting
  • Research Site
    Petah Tikva, 4941492, Israel
    Not yet recruiting
  • Research Site
    Ramat Gan, 52621, Israel
    Not yet recruiting
  • Research Site
    Tel Aviv, 64239, Israel
    Not yet recruiting
  • Research Site
    Milan, 20133, Italy
    Not yet recruiting
  • Research Site
    Milan, 20141, Italy
    Not yet recruiting
  • Research Site
    Misterbianco, 95045, Italy
    Not yet recruiting
  • Research Site
    Naples, 80131, Italy
    Not yet recruiting
  • Research Site
    Negrar, 37024, Italy
    Not yet recruiting
  • Research Site
    Reggio Emilia, 422122, Italy
    Not yet recruiting

Showing the first 100 of 151 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2029, 37 months after the start.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 37 months is close to that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 28, 2026
StartActual
May 4, 2026
Primary completionEst.
Jun 4, 2029
CompletionEst.
Jun 6, 2030
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
19 sites added — first sites in Belgium, Italy, Netherlands and Switzerland. 12 sites changed recruiting status (9 now recruiting, 2 now suspended, …)
Show 12 sites
  • Research Site · Phoenix, United StatesNot yet recruiting→Withdrawn
  • Research Site · Duarte, United StatesNot yet recruiting→Recruiting
  • Research Site · San Francisco, United StatesNot yet recruiting→Recruiting
  • Research Site · New York, United StatesNot yet recruiting→Recruiting
  • Research Site · Pittsburgh, United StatesNot yet recruiting→Recruiting
  • Research Site · Myrtle Beach, United StatesNot yet recruiting→Recruiting
  • Research Site · Nashville, United StatesNot yet recruiting→Recruiting
  • Research Site · Salt Lake City, United StatesNot yet recruiting→Suspended
  • Research Site · Melbourne, AustraliaNot yet recruiting→Recruiting
  • Research Site · Toronto, CanadaNot yet recruiting→Recruiting
  • Research Site · Montreal, CanadaNot yet recruiting→Recruiting
  • Research Site · Krakow, PolandNot yet recruiting→Suspended
Show 19 added (7 Italy, 3 Belgium, 3 Switzerland, 2 United States, 2 Netherlands, 1 Austria, 1 China)
  • Research Site · Westbrook, United States
  • Research Site · Cleveland, United States
  • Research Site · Vienna, Austria
  • Research Site · Ghent, Belgium
  • Research Site · Leuven, Belgium
  • Research Site · Liège, Belgium
  • Research Site · Suzhou, China
  • Research Site · Milan, Italy
  • Research Site · Milan, Italy
  • Research Site · Misterbianco, Italy
  • Research Site · Naples, Italy
  • Research Site · Negrar, Italy
  • Research Site · Reggio Emilia, Italy
  • Research Site · Rozzano, Italy
  • Research Site · Amsterdam, Netherlands
  • Research Site · Nijmegen, Netherlands
  • Research Site · Bern, Switzerland
  • Research Site · Geneva, Switzerland
  • Research Site · Zurich, Switzerland
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    19 sites added — first sites in Belgium, Italy, Netherlands and Switzerland. 12 sites changed recruiting status (9 now recruiting, 2 now suspended, …)
    Show 12 sites
    • Research Site · Phoenix, United StatesNot yet recruiting→Withdrawn
    • Research Site · Duarte, United StatesNot yet recruiting→Recruiting
    • Research Site · San Francisco, United StatesNot yet recruiting→Recruiting
    • Research Site · New York, United StatesNot yet recruiting→Recruiting
    • Research Site · Pittsburgh, United StatesNot yet recruiting→Recruiting
    • Research Site · Myrtle Beach, United StatesNot yet recruiting→Recruiting
    • Research Site · Nashville, United StatesNot yet recruiting→Recruiting
    • Research Site · Salt Lake City, United StatesNot yet recruiting→Suspended
    • Research Site · Melbourne, AustraliaNot yet recruiting→Recruiting
    • Research Site · Toronto, CanadaNot yet recruiting→Recruiting
    • Research Site · Montreal, CanadaNot yet recruiting→Recruiting
    • Research Site · Krakow, PolandNot yet recruiting→Suspended
    Show 19 added (7 Italy, 3 Belgium, 3 Switzerland, 2 United States, 2 Netherlands, 1 Austria, 1 China)
    • Research Site · Westbrook, United States
    • Research Site · Cleveland, United States
    • Research Site · Vienna, Austria
    • Research Site · Ghent, Belgium
    • Research Site · Leuven, Belgium
    • Research Site · Liège, Belgium
    • Research Site · Suzhou, China
    • Research Site · Milan, Italy
    • Research Site · Milan, Italy
    • Research Site · Misterbianco, Italy
    • Research Site · Naples, Italy
    • Research Site · Negrar, Italy
    • Research Site · Reggio Emilia, Italy
    • Research Site · Rozzano, Italy
    • Research Site · Amsterdam, Netherlands
    • Research Site · Nijmegen, Netherlands
    • Research Site · Bern, Switzerland
    • Research Site · Geneva, Switzerland
    • Research Site · Zurich, Switzerland
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07611110
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 28, 2026
Start date
May 4, 2026
Primary completion
Jun 4, 2029 (estimated)
Completion
Jun 6, 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Actinium-225

Start the discussion